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KEY POINTS 
 
• A novel mouse model elucidates the impact of Pml NB disruption on APL 
pathogenesis and response to targeted therapy.  
 
• The mode of action of this disruption appears to be via the perturbation of the 
NHEJ and HR pathways. 
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ABSTRACT 
 
A hallmark of acute promyelocytic leukemia (APL) is altered nuclear architecture, 
with disruption of PML nuclear bodies (NBs) mediated by the PML-RARα 
oncoprotein. To address whether this phenomenon plays a role in disease 
pathogenesis, we generated a knock-in mouse model with NB disruption mediated by 
two point mutations (C62A/C65A) in the Pml RING domain. While no leukemias 
developed in PmlC62A/C65A mice, these transgenic mice also expressing RARα linked 
to a dimerization domain (p50-RARα model) exhibited a doubling in the rate of 
leukemia, with a reduced latency period. Additionally, we found that response to 
targeted therapy with all-trans retinoic acid (ATRA) in vivo was dependent on NB 
integrity. PML-RARα is recognized to be insufficient for development of APL, 
requiring acquisition of cooperating mutations. We therefore investigated whether NB 
disruption might be mutagenic. Compared to wild-type cells, primary PmlC62A/C65A 
cells exhibited increased sister-chromatid exchange and chromosome abnormalities. 
Moreover, functional assays showed impaired homologous recombination (HR) and 
non-homologous end-joining (NHEJ) repair pathways, with defective localization of 
Brca1 and Rad51 to sites of DNA damage. These data directly demonstrate that Pml 
NBs are critical for DNA damage responses, and suggest that Pml NB disruption is a 
central contributor to APL pathogenesis. 
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INTRODUCTION 
 
Acute promyelocytic leukemia (APL) is one of the commonest subtypes of acute 
myeloid leukemia (AML), with the vast majority of cases harboring the t(15;17) 
chromosomal translocation, involving the fusion of the genes encoding PML 
(promyelocytic leukemia) and the transcription factor RARα (retinoic acid receptor 
alpha)1-3. The outcome for APL patients has been transformed with the advent of 
molecularly-targeted therapies, i.e. arsenic trioxide (ATO) and all-trans retinoic acid 
(ATRA), which bind to the PML and RARα moieties of PML-RARα, respectively. 
These two drugs act in synergy to trigger PML–RARα degradation, by promoting 
apoptosis (ATO) and cellular differentiation (ATRA), inducing clinical remission4-7. 
PML is localized in PML nuclear bodies (NBs)8-10, discrete subnuclear structures of 
which PML is a crucial component11-13. Indeed, PML not only promotes NB 
biogenesis and maintains its integrity3,14,15, but is also involved in the recruitment and 
localization of approximately one hundred proteins into this complex (e.g. SUMO-1, 
CBP, DAXX, BLM)16. The post-translational modifications of PML, including its 
SUMOylation, are critical steps in the formation of mature PML NBs3,17-19. PML NBs 
are dynamic multiprotein complexes16, involved in various major processes such as 
stem cell self-renewal, cell death, and transcription20. 
Cells utilize different DNA repair pathways depending on the type of damage, and the 
phase of the cell cycle in which the damage occurs. DNA double-strand breaks 
(DSBs) produced by ionizing radiation (IR), for example, can be repaired by two 
major mechanisms: the non-homologous end joining (NHEJ) and homologous 
recombination (HR) repair pathways. NHEJ, which is mostly active during the G1 
phase of the cell cycle, mediates direct ligation of the broken DNA ends in an error 
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prone manner. HR is, by contrast, largely error free, and arises in the G2 phase using 
sister chromatids as templates for repair. Failure in DNA DSB repair may lead to 
genomic instability, and consequently cancer predisposition21. 
Numerous studies have highlighted the importance of the capacity of the PML-RARα 
fusion protein to oligomerize (conferred by the PML moiety) in APL pathogenesis , in 
contrast to wild-type RARα which lacks this property22,23. Moreover, it is also 
unambiguous that PML-RARα expression has a major impact on nuclear architecture 
leading to NB disruption into nuclear microspeckles, which is a diagnostic hallmark 
of APL3. This phenomenon has been proposed as a key step in leukemogenesis24, but 
this has not been formally explored in vivo until now. Furthermore, NB disruption is 
reversed by ATO or ATRA treatment25, suggesting that normalization of nuclear 
architecture may be important for response to targeted therapies. To address these 
issues, we have generated a novel knock-in mouse model, where targeted Pml NB 
disruption was achieved through mutation of two key zinc-binding cysteine residues 
(C62A/C65A) in the RING domain of Pml. Our mouse model highlights the essential 
cooperative role of the NB disruption induced by PML-RARα expression in APL 
development, and the importance of re-formation of NBs in generating an efficient 
response to differentiating drug (ATRA). Additionally, our data reveal that Pml NBs 
are determinants of the quality of DNA damage repair via both NHEJ and HR repair 
pathways. 
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MATERIALS AND METHODS 
 
Animal experimental guidelines 
All animal experimentations were performed in accordance with the terms of UK 
Home Office guidelines. The home office project license number under which these 
experiments were conducted is PPL 70/7720. 
 
Transplantation experiments 
All transplant recipient mice were 8-12 weeks old at the time of transplantation. 
Unfractionated BM cells (0.5–1×106) were transplanted into sublethally irradiated 
mice (4.5 Gy) via tail vein injection. PML-RARα leukemic BM cells were 
transplanted into sub-lethally irradiated FVB/N Hsd mice. Moribund mice were 
humanely sacrificed, and leukemia was routinely confirmed by May-Grünwald 
Giemsa staining, peripheral blood analyses or independently confirmed by a 
veterinarian. 
Leukemia samples used for transplantation experiments were as follows: #1707, 
#M1/28, and #1787 for PmlWT+p50-RARα; #1403, #626, and #628 for 
PmlC62A/C65A+p50-RARα; #1111/3, #935/5, and #1097/1 for PML-RARα. 
For ATRA in vivo-experiments, placebo or ATRA 21-day release pellets (5 mg; 
Innovative Research of America) were subcutaneously implanted 7 days post-
transplantation as per manufacturer’s instructions. 
 
Immunoprecipitation and immunoblot analysis 
Cells were lysed on ice in RIPA buffer containing protease inhibitor cocktail (Roche) 
and 20 mM NEM (Sigma-Aldrich). Lysates were pre-cleared with Sepharose 4B 
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beads (GE Healthcare), and then immunoprecipitated with the relevant antibody or 
isotype control as previously described26. Immunoprecipitates and whole cell lysates 
were separated by SDS-PAGE and transferred to PVDF membranes (Millipore). 
Membranes were blocked in 5% BSA, and then incubated with primary antibodies 
overnight at 4ºC. Immunodetection was performed using ECL Western blotting 
substrate (ThermoFisher), or using infrared imaging (Odyssey LI-COR). 
 
Flow cytometry assays 
LSK population was defined as previously described27. Briefly, lineage-depleted 
(Dynabeads, ThermoFisher) BM cells were stained with fluorochrome-conjugated 
antibodies against Sca-1, and c-Kit (Biolegend), and the lineage cocktail (B220, CD3, 
CD4, CD8, Ter119, Mac-1, and Gr-1; Biolegend). CD11b/Gr-1 population analysis 
was performed as previously described28. Flow cytometry was performed on a BD 
LSRFortessa cell analyzer and data were analyzed with FlowJo software (Tree Star). 
 
In vivo cell cycle analysis 
Mice were injected with 50 mg/kg EdU (5-ethynyl-2’-deoxyuridine) 2 h before BM 
harvest29. Cells were processed using a Click-iT EdU Flow Cytometry Assay kit 
(ThermoFisher). 
 
Nitro blue tetrazolium (NBT) reduction assay 
0.1% of NBT (Sigma-Aldrich) was added to leukemic BM cells on poly-D-lysine 
coated coverslips, and incubated in a 5% CO2 incubator at 37°C. Images were taken 
under Eclipse Ti-E Inverted Imaging System (Nikon), and auto-analyzed with the NIS 
software. At least 1100 cells were counted per sample. 
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NHEJ and HR activity assay 
All cell types were nucleofected using Amaxa kit (Lonza) following the 
manufacturer’s instructions. Briefly, cells were co-transfected with linearized NHEJ 
reporter plasmid or linearized HR reporter plasmid (kind gifts of Dr Vera Gorbunova; 
U. Rochester) and pDsRed-Express-N1 plasmid (Clontech; as transfection efficiency 
control) as previously described30,31. Lineage-depleted BM cells were isolated 12 h 
before nucleofection32. Flow cytometry was performed on a BD LSRFortessa cell 
analyzer and data were analyzed with FlowJo software (Tree Star). 
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RESULTS 
 
Generation of a PmlC62A/C65A knock-in mouse model, and PmlC62A/C65A+p50-
RARα mice 
To investigate the functional consequences of Pml NB disruption, we engineered a 
knock-in mouse model by substituting two zinc-binding cysteine residues for two 
alanine residues located in the RING domain at positions 62 and 65, via site-directed 
mutagenesis and subsequent homologous recombination in mouse ES cells 
(supplemental Figure 1A-E). For simplicity, homozygous mutant mice will be 
referred to as PmlC62A/C65A. PmlC62A/C65A mice are developmentally normal, and do not 
die of spontaneous leukemias or tumors. 
The importance of RARα dimerization in APL pathogenicity has been reported 
previously33. To explore whether RARα dimerization operates conjointly with NB 
disruption, PmlC62A/C65A mice were crossbred with p50-RARα transgenic mice34, in 
order to generate PmlC62A/C65A+p50-RARα mice; here, RARα dimerization is 
artificially forced by linking to the dimerization domain of the NF-кB p50 
subunit33,34. All the mouse models used in this study have been color-coded, as 
summarized in supplemental Figure 1F. 
 
PmlC62A/C65A expression causes dispersion of NB constituents, deficiency of Pml 
SUMOylation, and expansion of the LSK compartment 
We next investigated whether endogenous PmlC62A/C65A expression induced Pml NB 
disruption, as previously described when overexpressed in human cell lines15,35,36. We 
performed immunofluorescence staining to analyze the localization of well-known 
NB constituents. Initially, Pml staining was used as a first-line control of Pml NB 
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disruption; this confirmed that PmlC62A/C65A was dispersed in primary mouse 
embryonic fibroblasts (MEFs) compared to wild-type Pml (PmlWT). Additionally, 
while Daxx, Cbp and Sumo-1 formed clear and bright foci in PmlWT MEFs, a diffuse 
nuclear pattern was observed in PmlC62A/C65A and Pml-/- cells17,37 (Figure 1A). We 
confirmed that these differences did not result from variations in the level of protein 
expression (Figure 1B). The PmlC62A/C65A mutant replicated the NB disruption seen in 
primary human APL cells, with dispersion of PML and NB constituents (e.g. DAXX), 
and as shown in the PML-RARA-expressing NB4 human cell line. As expected, 
treatment of NB4 cells with ATRA led to re-localization of DAXX and PML into 
NBs38 (Figure 1C). 
The PML RING domain is essential for PML SUMOylation14,15,37,39. 
Immunoprecipitations of Sumo-1 or Sumo-2/3 revealed that endogenous PmlWT was 
SUMOylated in MEFs at basal level, and hyper-SUMOylated following ATO 
treatment (Figure 1D). Moreover, post-ATO treatment, PmlWT was found to be 
ubiquitinated. None of these smears of bands were detected in PmlC62A/C65A cells, or as 
expected in Pml-/- cells (negative control)26 (Figure 1D). Collectively, we confirmed 
that the C62A/C65A mutation induces NB disruption in a fashion similar to that 
observed in the context of PML-RARα. These data also demonstrate that the integrity 
of the RING domain is required not only for PML SUMOylation, but also for the 
ATO induced-PML degradation pathway. 
In vivo, PmlC62A/C65A mice did not exhibit alterations in peripheral blood count 
parameters. However, the number of Lin-Sca-1+c-Kit+ (LSK) hematopoietic stem and 
progenitor cells was greatly increased, and this increase was even more significant 
than that seen in the absence of Pml (i.e. Pml-/- mice) (Figure 1E; supplemental 
Figure 2). Cell cycle analysis revealed that the higher number of LSK cells in 
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PmlC62A/C65A mice, and to a lesser extend in Pml-/- mice, was attributable, at least in 
part, to an acceleration of cell cycle progression (Figure 1F-G). Unlike LSK cells, 
PmlWT, Pml-/- and PmlC62A/C65A primary MEFs did not present any variations in their 
cell cycle nor cell death profiles (supplemental Figure 3), thus making MEFs a more 
suitable model to analyze downstream cellular functions. 
 
Pml NB disruption promotes APL pathogenesis 
While no disease was detected over an 18-month observation period in PmlWT (0/249) 
or PmlC62A/C65A (0/251) mice, both PmlWT+p50-RARα (15/252) and 
PmlC62A/C65A+p50-RARα (32/251) mice developed APL spontaneously (Figure 2A-
B). These leukemias were characterized by hyperleukocytosis, anemia and 
thrombocytosis, and validated by post-mortem examination revealing, for example, 
pale bone marrow (BM) and splenomegaly (mean weight of healthy adult spleen, 
25.75 mg; PmlWT+p50-RARα leukemic spleen, 458 mg; PmlC62A/C65A+p50-RARα 
leukemic spleen, 642 mg; PML-RARα leukemic spleen as control, 580 mg). The 
cumulative incidence of APL differed significantly between PmlWT+p50-RARα and 
PmlC62A/C65A+p50-RARα genotypes, with a frequency at 18 months of 6.8% and 
13.8%, respectively, leading to a penetrance comparable to that observed in PML-
RARα transgenic models40-42 (Figure 2A). Moreover, the latency period before the 
onset of leukemia was significantly reduced in the context of NB disruption compared 
to PmlWT+p50-RARα (to 213 days of age versus 310 days; p<0.008; Figure 2A). 
These results demonstrate cooperativity between NB disruption and RARα 
dimerization in the initiation of APL. 
We then assessed APL-initiating activity by transplanting primary APL-derived cells 
into recipient mice. The vast majority of mice transplanted with leukemic 
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PmlWT+p50-RARα (11/14) or PmlC62A/C65A+p50-RARα (6/8) unsorted BM cells 
developed APL (Figure 2C). The latency period to disease was similar to that 
previously observed upon transplantation of PML-RARα leukemic blasts40. None of 
the mice which received a mock transplant (PBS) developed any disease. Secondary 
and tertiary transplants of unsorted BM cells retained the capacity to initiate APL for 
these three genotypes. 
The similarities we observed between PmlC62A/C65A+p50-RARα and PML-RARα mice 
thus strengthen evidence for the crucial contribution of Pml NB disruption to APL 
pathogenesis. 
 
Pml NBs are involved in the response to ATRA treatment 
Induction of myeloid differentiation is the hallmark of response to ATRA43. To 
analyze the effect of NB disruption on ATRA-induced differentiation, we firstly 
performed an in vitro NBT assay. When unsorted leukemic BM cells, isolated from 
recipients transplanted with PML-RARα or PmlWT+p50-RARα cells, were incubated 
with ATRA, the percentage of differentiated cells was greatly enhanced compared to 
cells treated with the vehicle control (DMSO) (Figure 3A). Interestingly, 
PmlC62A/C65A+p50-RARα cells treated with ATRA did not present a significant 
increase in the percentage of differentiated cells (Figure 3A). The absence of 
granulocytic differentiation following ATRA exposure in PmlC62A/C65A+p50-RARα-
derived APL cells was confirmed by analysis of CD11b and Gr1 expression (Figure 
3B). In vivo, ATRA-treated mice post-transplantation also confirmed these results: 
survival was significantly improved only for PML-RARα and PmlWT+p50-RARα 
transplanted mice, compared to placebo-treated mice (Figure 3C). These data reveal 
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the importance of Pml NB re-formation for an effective response to the differentiating 
drug. 
 
Pml NBs are involved in the maintenance of genome integrity and essential for 
optimal DNA DSB repair via the NHEJ and HR pathways 
The PML-RARA translocation is undoubtedly an initiating event in APL pathogenesis, 
but is not sufficient by itself for the full development of APL. Indeed, it is now well-
established that APL is a multistep disease, requiring additional cooperating 
mutations, thus explaining the long latency period prior to leukemia onset44-48. To 
determine whether the three different genotypes generated APL with similar 
mutational spectra, we performed whole-exome sequencing on samples from 
PmlWT+p50-RARα and PmlC62A/C65A+p50-RARα spontaneous leukemias, and on 
PML-RARα transplant samples. Interestingly, some of the mutated genes were 
common to human APL (e.g. Kras, Ptpn11 and Usp9y) or human AML (e.g. Pten and 
Jak2)48-51, and some of the copy number variants were common to human APL/AML 
(e.g. Kdm6a and Ezh2) or human myelodysplastic syndromes (e.g. Cul1)46,52,53 
(supplemental Figure 4 and supplemental Table 1). 
Then, we speculated that loss of NB integrity might affect DNA DSB repair 
pathways13,54. To investigate the efficiency of the NHEJ and HR pathways, we used a 
well-established system of reporter assays30,31. Pml-/- primary MEFs did not exhibit 
any defect in the NHEJ pathway when compared to PmlWT cells (Figure 4A and 
supplemental Figure 3A). They did, however, present a significant reduction in the 
efficiency of the HR pathway, as previously reported13. Strikingly, both NHEJ (with 
Compatible and Incompatible DNA ends) and HR pathway activities were diminished 
in PmlC62A/C65A MEFs. Similar results for the NHEJ pathway have been obtained with 
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lineage-depleted BM cells isolated from the PmlC62A/C65A mouse model, compared to 
PmlWT (Figure 4B). The forced dimerization of RARα also affected the efficiency of 
the NHEJ pathway to a level similar to that observed in PmlC62A/C65A cells (Figure 
4B). Moreover, an additive effect was observed in PmlC62A/C65A+p50-RARα cells 
compared to PmlWT+p50-RARα cells (Figure 4B). Importantly, similar results were 
obtained with an inducible PML-RAR -expressing cell line (Figure 4C), thus 
reinforcing the resemblance observed between PmlC62A/C65A– and PML-RARα–
induced NB disruption. 
To determine whether these defects in DNA DSB repair pathways were due to a 
reduced kinetics of repair and/or reduced quality of repair, we analyzed MEF 
metaphase spreads. First, these revealed a significantly greater number of 
chromosome aberrations in PmlC62A/C65A cells in response to ionizing radiation (IR), 
compared to PmlWT and Pml-/- cells (Figure 4D). Second, a significantly higher 
number of spontaneous sister chromatid exchange (SCEs) was also found in 
PmlC62A/C65A cells, compared to WT cells (Figure 4E). Additionally, the rate of SCE 
formation in PmlC62A/C65A cells was similar to that observed in Pml-/- cells. 
Altogether, these data indicate that NB dispersion gives rise to a higher level of 
recombination activity in primary cells, and further suggests that mice lacking Pml 
NBs may have an unstable genome. 
 
Investigation of the defective NHEJ pathway in PmlC62A/C65A cells uncovers 
53BP1 and Brca1 alteration 
We tracked the time-course of γH2AX foci formation and disappearance, a well-
established indicator of DNA DSBs, in MEFs and in lineage-depleted BM cells, pre- 
and post-IR exposure (supplemental Figure 5 and 6A-B). An obvious induction of 
 15
γH2AX foci was observable 1 h post-IR, compared to untreated cells. The kinetics of 
repair were identical for all genotypes studied (supplemental Figure 6A-B). This 
result was confirmed by Western blot analyses, since equivalent levels of γH2AX, 
between genotypes, were observed at each time point (supplemental Figure 6C). 
Examining the NHEJ pathway-specific factors, we found that the number of 53BP1 
foci was altered in PmlC62A/C65A MEFs, with no variation in protein expression 
(Figure 5A, supplemental Figure 6C and 7). Indeed, PmlC62A/C65A MEFs presented 
significantly more 53BP1 foci in the context of spontaneous DNA lesions, when 
compared to PmlWT and Pml-/- cells. 53BP1 was found to co-localize normally with 
γH2AX, as shown in Figure 5B. 53BP1 and Brca1 are central in the regulation of the 
balance between NHEJ and HR pathways55. Interestingly, following IR exposure, 
53BP1 and Brca1 foci co-localized at a higher level in PmlC62A/C65A MEFs (mean: 
43.81%) compared to PmlWT and Pml-/- cells (mean: 25.27% and 25.82% respectively; 
Figure 5C-D). These data revealed that Pml NB integrity is required for correct 
functional crosstalk between DNA repair proteins involved in the switch between 
NHEJ and HR pathways. Consequently, the erroneous localization of Brca1 in 
PmlC62A/C65A cells may also be part of the disturbance observed in the HR pathway. 
 
Investigation of the defective HR pathway reveals the importance of Pml NB 
integrity for the correct localization of Rad51 at DSBs 
We then analyzed two main factors of the HR pathway: Blm and Rad51. 
Unfortunately, none of the commercial antibodies tested against Blm produced 
positive signals in immunofluorescence assays. As a surrogate, we therefore 
overexpressed GFP-Blm in primary MEFs (Figure 6A). In order to determine 
whether overexpressed Blm accumulates in a fashion similar to the endogenous 
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protein, co-staining with Pml was performed in wild-type cells. As expected, Blm and 
Pml co-localized56 (Figure 6B). In a similar manner to 53BP1, the number of foci for 
Blm and Rad51 differed at basal level, reflecting a disturbance in the HR pathway in 
PmlC62A/C65A and Pml-/- MEFs, compared to PmlWT cells (Figure 6C-D, supplemental 
Figure 8 and 9). When protein localization was analyzed, no mislocalizations were 
observed for Blm foci. Regarding Rad51, confocal analyses revealed strikingly that 
Rad51 minimally co-localized with γH2AX in PmlC62A/C65A and Pml-/- cells, compared 
to PmlWT MEFs (Figure 6E). These observations were validated by co-
immunoprecipitation experiments. Notably, while the same amount of Rad51 was 
immunoprecipitated, the amount of γH2AX pulled down was lower in PmlC62A/C65A 
and Pml-/- compared to PmlWT lysates (Figure 6F). 
Collectively, our data provide further evidence that Pml NBs are essential for 
effective DNA repair response, and that their disruption is in part responsible for the 
deficiency observed in the context of PML-RARα expression. 
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DISCUSSION 
 
APL development is invariably associated with translocations of the RARA gene, and 
numerous studies have been carried out to determine how the resulting fusions 
contribute to the pathogenesis of this disease. These include studies of the importance 
of the fusion partners, but these have been directed more towards their 
oligomerization potential. As a result, the role played by Pml NB disruption in APL 
pathogenesis had not been studied in a comprehensive way. Nevertheless, two 
particular studies have provided preliminary evidence for the importance of Pml NB 
disruption in leukemogenesis. Using truncated versions of the PML-RARα fusion 
protein, they hypothesized that the PML moiety was required not solely for the 
dimerization of RARα, and that the observed Pml NB disruption might play an active 
role in APL pathogenesis57,58. Here, we used a novel knock-in mouse model, in which 
Pml NBs are disrupted in a similar fashion to that observed in the context of PML-
RARα expression, in order to dissect their impact. 
Using this model, we showed definitive evidence for the involvement of Pml NB 
disruption in APL initiation, in synergy with the forced dimerization of RARα. We 
also showed that an effective response to ATRA treatment requires Pml NB integrity. 
These data validate the proposed hypothesis that NBs contain essential factors for 
nuclear hormone receptor signal transduction11,59,60, and demonstrate that the wild-
type Pml allele plays an important role in tumor regression following ATRA 
treatment for PML-RARα APL61. These points are of importance since ATRA and its 
derivatives are under investigation not only for the treatment of other AML 
subtypes62,63, but also for other malignancies64-68. Furthermore, PmlC62A/C65A+p50-
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RARα mouse model recapitulates substantially APL pathogenesis as observed in 
PML-RARα APL mouse models. 
Previous studies have investigated the connection between Pml NBs and DNA 
damage repair. However, owing to the models used, PML-RARα54,69 or Pml-/- 
cells13,70, it was impossible to establish a direct link between the two. On the one 
hand, the consequences of disruption could not be disassociated from those due to 
alterations in the RARα signaling; on the other hand, the absence of Pml expression is 
not necessarily equivalent to Pml mislocalization and Pml NB disruption, as it has 
been exemplified in this study. Indeed, we report here that both NHEJ and HR repair 
pathways are drastically altered by the loss of Pml NB integrity, while only the HR 
pathway was impaired in Pml-/- cells. Repair through NHEJ was considerably more 
altered in PmlC62A/C65A+p50-RARα cells than in PmlC62A/C65A or PmlWT+p50-RARα 
cells, revealing that Pml NB disruption and the forced dimerization of RARα had a 
cooperative effect on DNA damage responses. Surprisingly, no alterations in the 
kinetics of repair following IR exposure were noticeable, since clearance of γH2AX 
foci was similar in all genotypes analyzed. Based on these results, it was possible to 
refute the hypothesis that the higher number of γH2AX foci observed in PML-RARα 
cells71 is exclusively due to Pml NB dispersion69,70. Also, PML-RARα is able to 
initiate leukemia, but additional events are needed to lead to complete leukemic 
transformation as observed in various transgenic mouse models40-42. It is thus 
plausible that the acquisition of cooperating mutations46,72 is facilitated by the loss of 
Pml NB integrity. This hypothesis is further strengthened by published reports, which 
have established that the majority of de novo mutations are random events in 
AML/APL48-50. 
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The NHEJ and HR pathways involve a large number of different factors, including 
53BP1 for the NHEJ pathway, and Brca1, Blm and Rad51 for the HR pathway21. 
Here, we found an excess of 53BP1, Blm and Rad51 foci in PmlC62A/C65A cells 
compared to PmlWT cells. Interestingly, in recent years, SUMO and ubiquitin signals 
have been characterized as essential components in DNA damage responses55,73, and 
indeed, deficient SUMOylation of Blm and/or Rpa has been shown to impair Rad51 
localization74-76. Our results, therefore, suggest a scenario in which the putative 
incorrect SUMOylation of Blm and/or Rpa (due to SUMOs being inadequately 
localized in PmlC62A/C65A cells) might partially explain our observation of Rad51 
mislocalization. 53BP1 foci, which were found in excess only in the context of 
PmlC62A/C65A expression, were still located at sites of damage, suggesting that the 
DNA DSB-specific histone signature, including ubiquitination, is not affected by Pml 
NB disruption77. It would be of interest, therefore, to carry out further analyses of 
53BP1 phosphorylation, the localization of its partners (e.g. Rif1), and indubitably the 
SUMOylation of 53BP1 itself78,79, in order to establish the causes and consequences 
of this excess of 53BP1 foci. Moreover, 53BP1 dysregulation might also have 
repercussions in the HR pathway, since 53BP1 and Brca1 are key regulators of the 
balance between NHEJ and HR repair pathways during the S-G2 phases of the cell 
cycle80-84. Also, the SUMO pathway is an important regulator of Brca1 functions85-87. 
Finally, the discrepancies observed between the absence of Pml NBs and their 
disruption (i.e. Pml-/- versus PmlC62A/C65A mutants) could also be linked to their 
distinct impact on Sumo-2/3: while Sumo-2/3 formed abnormally large foci in Pml-/- 
cells, a diffuse pattern was observed in PmlC62A/C65A cells (supplemental Figure 
10A). These data are consistent with the role of Pml as a dynamic anchor regulated by 
SUMOylation3,16. Indeed, since Pml is expressed in PmlC62A/C65A cells, and because 
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the SUMOylome is severely reduced but still extant (supplemental Figure 10B-E), 
some proteins could still be recruited by Pml through its SUMO-interaction motif 
(SIM), for example, and might subsequently become sequestrated and/or 
mislocalized. In accordance with this hypothesis, our finding that 53BP1 
SUMOylation was not affected in the same way in Pml-/- and PmlC62A/C65A cells could 
explain, at least partially, the disparity observed in the NHEJ pathway (supplemental 
Figure 10F-G). Thus, further study is needed to establish whether Pml NB disruption 
significantly affects the SUMOylome, and its potential downstream impacts on DNA 
damage responses (supplemental Figure 10 and 11). 
Overall, we found strong evidence for the essential pathogenic role of PML-RARα 
expression-induced NB disruption in APL development, and also of the importance of 
NB re-formation for an effective response to targeted therapy. Our data also underline 
the significant contribution of Pml NBs to the effectiveness of DNA damage repair 
processes, and the manner in which their disruption, mediated by the PML-RARα 
oncoprotein, can assist APL pathogenesis. 
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LEGENDS 
 
Figure 1. PmlC62A/C65A expression induces mislocalization of NB constituents, Pml 
SUMOylation deficiency, and expansion of the LSK compartment. (A) 
Representative confocal microscopy images are presented for Pml (green), Daxx, Cbp 
and Sumo-1 (red) staining in PmlWT, PmlC62A/C65A, and Pml-/- MEFs. Nuclei were 
counterstained with DAPI (blue). Scale bar, 10 μm. (B) Expression levels 
demonstrated by Western blot analysis of whole cell lysates extracted from PmlWT, 
PmlC62A/C65A, and Pml-/- MEFs. The asterisk indicates a non-specific band. Tubulin 
was used as loading control. (C) Representative images of DAXX (red) and PML 
(green) staining in NB4 cells treated with DMSO (vehicle control) or ATRA (1μM). 
Nuclei were counterstained with DAPI (blue). Scale bar, 10 μm. (D) MEFs were 
treated with or without ATO (1μM) for 1 h, as indicated, followed by 
immunoprecipitation (IP) by control IgG (CTRL) or with antibodies against the 
indicated protein. The immunoprecipitates were analyzed by immunoblot (IB) with an 
anti-Pml antibody in order to reveal the SUMOylated or ubiquitinated forms of Pml. 
Data shown are representative of three independent experiments. (E) Relative number 
of Lin-Sca-1+c-Kit+ (LSK) cells in BM at 8 weeks (n≥3). (F) Cell cycle phase 
distribution of LSK cells labeled with Click-iT EdU in vivo (n≥3). (G) Representative 
dot plots of cell cycle status of LSK population. (E and F) Two-tailed unpaired 
Student’s t test analyses were performed. 
 
Figure 2. Pml NB disruption improves induction of APL. (A) Kaplan-Meier curve 
showing cumulative incidence of APL in PmlWT (n=249), PmlC62A/C65A (n=251), 
PmlWT+p50-RARα (n=252), and PmlC62A/C65A+p50-RARα (n=251). (B) Top panels: 
 30
Representative pictures of blood smear of moribund PmlC62A/C65A+p50-RARα mice 
showing hyperleukocytosis (May-Grünwald Giemsa staining). Bottom panel: 
Representative spleens of PmlWT healthy control and PmlC62A/C65A+p50-RARα 
leukemic mice. (C) Kaplan-Meier survival curve of mouse primary recipients 
transplanted with PmlWT+p50-RARα (n=14) and PmlC62A/C65A+p50-RARα (n=8) 
leukemic BM cells, from three independent leukemias each. Mouse recipients 
transplanted with PML-RARα leukemic BM cells (n=13) from three independent 
leukemic samples. This graph represents pooled data from two independent 
experiments. (A and C) Log-rank tests were used to compare survival curves.  
 
Figure 3. Response to ATRA treatment is compromised when Pml NBs are 
disrupted. (A) Differentiation of BM cells from secondary recipients determined by 
in vitro NBT assay following treatment with DMSO (vehicle control) or ATRA 
(1μM) (n≥4). A minimum of 1100 cells were counted per sample using the Nikon NIS 
Elements C software. Two-tailed unpaired Student’s t test analysis was performed. 
(B) Representative contour plots of leukemic blasts treated with DMSO (vehicle 
control) or ATRA (1µM) for the myeloid differentiation markers CD11b and Gr1. (C) 
Survival of secondary recipients treated with ATRA (5mg) or placebo pellets from 
day 7 post-transplantation (n≥5). This graph represents pooled data from three 
independent experiments. Log-rank test was used. T= Transplantation; I= 
Implantation.  
 
Figure 4. Efficiency of NHEJ and HR altered by Pml NB disruption. (A) 
Efficiency of NHEJ-C (Compatible DNA ends), NHEJ-I (Incompatible DNA ends), 
and HR pathways in primary MEFs (n=3). The efficiency of repair was measured by 
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quantification of GFP fluorescence expression, which can only occur when linearized 
plasmids are accurately ligated (NHEJ-C) or repaired (NHEJ-I and HR). (B) 
Efficiency of NHEJ-C in lineage-depleted BM cells (n≥5). (C) Efficiency of NHEJ-C, 
NHEJ-I and HR in U937-Empty vector and U937-PR9 cell lines, 48 h after ZnSO4 
treatment for induction of PML-RARα expression (n=4). Western blot analysis of 
whole cell lysates from U937-Empty vector and U937-PR9 cell lines treated with (+) 
or without (-) ZnSO4 confirming PML-RARα expression. Tubulin was used as 
loading control. (A to C) Two-tailed unpaired Student’s t test analyses were 
performed. (D) Percentage of chromosomal aberrations (breaks, gaps and 
rearrangements) in MEFs at the indicated time post-IR (n>40 metaphase spreads from 
three independent experiments). Representative images inset of a chromatid 
rearrangement and a chromatid gap. (E) Sister chromatid exchanges (SCEs) rate per 
chromosome in MEFs, non-treated or treated with IR (n>30 metaphase spreads from 
three independent experiments). Representative image inset of SCEs. (D and E) Two-
tailed Mann-Whitney U-test was used. 
 
Figure 5. Elevated co-localization between 53BP1 and Brca1 foci in PmlC62A/C65A 
cells. (A) Ratio of 53BP1 foci in MEFs over a 24 h time course following IR exposure 
(n=3 per time point). Two-tailed unpaired Student’s t test analysis was performed. *, 
P < 0.05. (B) Representative images of irradiated MEFs immunostained for 53BP1 
(red), γH2AX (green) and DAPI (blue). Scale bar, 10 μm. (C) Quantification of 
53BP1 and Brca1 foci co-localization 1 h post-IR in MEFs from three independent 
experiments. Only cells co-expressing 53BP1 and Brca1 foci were counted. 
Significance was assessed by two-tailed Mann-Whitney U-test. (D) Representative 
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images of irradiated MEFs immunostained for 53BP1 (green), Brca1 (red) and DAPI 
(blue). Scale bar, 10 μm. 
 
Figure 6. Reduced co-localization between Rad51 and γH2AX foci in PmlC62A/C65A 
and Pml-/- cells. (A) Representative images of PmlWT, Pml-/- and PmlC62A/C65A MEFs 
overexpressing GFP-Blm (GFP-Blm, green; DAPI, blue). Scale bar, 10 μm. (B) 
Representative co-staining images of Blm/Pml in PmlWT MEF overexpressing GFP-
Blm (GFP-Blm, green; Pml, red; DAPI, blue). Scale bar, 10 μm. (C) Ratio of GFP-
Blm foci in MEFs (n=3). (D) Ratio of Rad51 foci in MEFs over a 24 h time course 
following IR exposure (n=3 per time point). (C and D) Two-tailed unpaired Student’s 
t test analyses were performed. *, P < 0.05; **, P < 0.01. (E) Representative images of 
irradiated MEFs immunostained for Rad51 (red), γH2AX (green) and DAPI (blue). 
Scale bar, 10 μm. (F) Co-immunoprecipitation experiments. Cells treated without (-) 
or 1 h post-IR (+) exposure were lysed and immunoprecipitated (IP) with anti-Rad51 
antibody and immunoblotted with anti-γH2AX antibody. Input is shown in the lower 
panels. The blots shown are representative of three independent experiments.  
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